Streetbeat News

HRMY

Harmony Biosciences Holdings, Inc.

https://www.harmonybiosciences.com

Industry

Biotechnology

Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, develops and commercializes therapies for patients with rare neurological disorders in the United States. Its product, WAKIX is a medication for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. The company was formerly known as Harmony Biosciences II, Inc. and changed its name to Harmony Biosciences Holdings, Inc. in February 2020. Harmony Biosciences Holdings, Inc. was incorporated in 2017 and is based in Plymouth Meeting, Pennsylvania.

Open

34.52

Mkt cap

2B

Volume

220K

High

35.37

P/E Ratio

16.50

52-wk high

41.61

Low

34.28

Div yield

N/A

52-wk low

22.89

Goldman Sachs has downgraded Harmony Biosciences from Neutral to Sell and reduced its price target from $40 to $31. This has resulted in a decrease in the trading price of Harmony Biosciences shares.

Portfolio Pulse from Benzinga Newsdesk

September 25, 2023 | 2:04 pm

Goldman Sachs analyst Corinne Jenkins has downgraded Harmony Biosciences (NASDAQ:HRMY) from Neutral to Sell and lowered the price target from $40 to $31.

Portfolio Pulse from Benzinga Newsdesk

September 25, 2023 | 12:09 pm

Needham analyst Ami Fadia has reiterated a 'Buy' rating on Harmony Biosciences (NASDAQ:HRMY) and maintained a price target of $66.

Portfolio Pulse from Benzinga Newsdesk

September 22, 2023 | 3:09 pm

The FDA has responded to Scorpion Capital's citizen petition, stating that it has been unable to reach a decision due to the complex issues raised requiring extensive review and analysis by agency officials.

Portfolio Pulse from Benzinga Newsdesk

September 21, 2023 | 7:53 pm

Scorpion Capital has received an interim response from the FDA regarding their petition to withdraw approval of Harmony Biosciences' drug Wakix. The FDA has stated that the petition raises complex issues requiring extensive review and analysis. The final decision is expected within two weeks.

Portfolio Pulse from Benzinga Newsdesk

September 21, 2023 | 7:50 pm

Mizuho analyst Graig Suvannavejh has maintained a 'Buy' rating on Harmony Biosciences (NASDAQ:HRMY) and kept the price target at $54.

Portfolio Pulse from Benzinga Newsdesk

September 19, 2023 | 2:22 pm

Harmony Biosciences (NASDAQ:HRMY) has received 9 analyst ratings in the last quarter, with 6 being bullish, 3 somewhat bullish, and none being bearish or indifferent. The average 12-month price target for the company is $63.67, a decrease of 3.05% from the previous average of $65.67.

Portfolio Pulse from Benzinga Insights

September 07, 2023 | 9:00 pm

Harmony Biosciences has been granted Orphan Drug designation for Pitolisant, leading to a rise in its share prices.

Portfolio Pulse from Benzinga Newsdesk

September 07, 2023 | 1:13 pm

Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) has announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug designation to pitolisant for the treatment of idiopathic hypersomnia (IH).

Portfolio Pulse from Benzinga Newsdesk

September 07, 2023 | 12:07 pm

Berenberg analyst Caroline Palomeque has initiated coverage on Harmony Biosciences (NASDAQ:HRMY) with a Buy rating and a price target of $59.

Portfolio Pulse from Benzinga Newsdesk

September 07, 2023 | 9:53 am

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.